THE IMPACT OF CMV-SEROPOSITIVITY ON OUTCOMES AFTER ALLOGENEIC STEM CELL TRANSPLANTATION IN THE ERA OF LETERMOVIR IN AML AND MDS PATIENTS

Prevymis (letermovir) - Merck (MSD)

https://ebmt2026.abstractserver.com/programme/#/details/presentations/1388

Lina Kolloch1; Judith Boschke2; Christian Reicherts1; Julian Ronnacker1; Hanna Schneider1; Jörn Albring1; Julia Marx1; Eva Eßeling1; Georg Lenz1; Matthias Stelljes1

Mar 14, 2026